Iris Medicine

Executive Summary

Iris Medicine is a preclinical-stage biotechnology company developing a novel RNA therapy platform based on small binding RNA (sbRNA) to treat repeat expansion disorders. The company's technology is designed to be allele-selective, directly targeting expanded repeat sequences that cause diseases such as Huntington's disease and various spinocerebellar ataxias. Unlike many genetic therapies, Iris Medicine's approach is non-viral and redosable, offering potential advantages in safety, tolerability, and broad applicability across patient populations with diverse repeat expansion mutations. Founded in 2020 and based in Cambridge, MA, the company is at the forefront of addressing the root cause of these devastating neurological disorders. As a preclinical entity, Iris Medicine has not yet disclosed specific financial details or clinical trial timelines. The company's near-term focus is on advancing its lead program through IND-enabling studies, generating proof-of-concept data, and establishing potential partnerships with academic or industry collaborators. Success in these milestones would de-risk the platform and pave the way for first-in-human trials. The sbRNA platform represents a promising approach in the expanding field of RNA therapeutics, targeting diseases with high unmet need and limited treatment options.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-enabling studies for lead program30% success
• Q4 2026Announcement of strategic collaboration or licensing deal25% success
• Q1 2027IND submission to FDA for first candidate20% success